I took liberties with the exact wording, but I'm referring to this treatment being developed:
http://www.riken.jp/en/pr/press/2016/20160402_1/. This specific press release is brief, but there was discussion on the RIKEN site from the team about applying this to producing hair for cases of congenital alopecia in patients that have no zone to harvest from (a solution that would presumably solve DUPA). This is brought up again here:
http://www.organ-technol.co.jp/uploads/2018/06/98a3d5caabf1c7829941ab2d5caf20f8.pdf. "Our plan is to start a clinical trial of hair follicle regenerative medicine for male Androgenetic Alopecia patients, and then to expand the indication to female pattern alopecia, scarring alopecia, and congenital alopecia." The assumption is that they're working on targeting the most widespread demographic, and gradually moving towards solutions for more niche segments of the market. There's more on this, and I'll do my best to find more in-depth sources.